Heat Biologics To Present New Data on Trial

Pharmaceutical Investing

Heat Biologics will present a new poster from a Phase II trial on HS-410 treating non-muscle invasive bladder cancer at the 2017 American Association of Clinical Oncologists annual meeting.

Heat Biologics (NASDAQ:HTBX) will present a new poster from a Phase II trial on HS-410 treating non-muscle invasive bladder cancer at the 2017 American Association of Clinical Oncologists annual meeting.
As quoted in the press release:

Poster Presentation Details:
Title: Immune response results from vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC).
Date and Time: Sunday, June 4, 8:00 AM to 11:30 AM
Poster Number: 209

Click here to read the full press release.